Finance

Lists
Why is TRDA up 7.20%?
Dive Deeper
TRDA:NASDAQ
Entrada Therapeutics Inc
$5.06
+7.20%
(+0.34) 1D
$5.06
0.00% (0.00)
After hours
Closed: Nov 4, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRDA...
Open
$4.83
High
$5.12
Low
$4.60
Mkt. cap
197.02M
Avg. vol.
398.74K
Volume
497.63K
52-wk high
$16.45
52-wk low
$4.11
EPS
-$3.97
Beta
-0.19
Shares outstanding
38.94M
No. of employees
152
Open
$4.83
High
$5.12
Low
$4.60
Mkt. cap
197.02M
Avg. vol.
398.74K
Volume
497.63K
52-wk high
$16.45
52-wk low
$4.11
EPS
-$3.97
Beta
-0.19
Shares outstanding
38.94M
No. of employees
152
News stories
From web sources and news partners
About Entrada Therapeutics Inc
CEO-
Employees152
Founded2016
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Industry-
Websiteentradatx.com
Analyst ratings
Based on 5 analysts giving stock ratings to TRDA in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for TRDA in the last 3 months.
Highest
Current $5.06
$25.00 (+394.07%)
Average
$19.67 (+288.74%)
Lowest
$11.00 (+117.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Hold
Reiterated
-
-
10/19/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$25.00
+394.1%
10/15/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$23.00
+354.5%
09/03/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
$11.00
+117.4%
08/12/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/05/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$17.00
+236%
06/05/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/07/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
-
-
04/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.61M
1.30M
875.00K
898.00K
Cost of goods sold
38.36M
32.26M
33.05M
35.37M
Cost of revenue
38.36M
32.26M
33.05M
35.37M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.30M
9.35M
10.12M
10.49M
Operating expense
10.30M
9.35M
10.12M
10.49M
Total operating expenses
48.66M
41.61M
43.18M
45.86M
Operating income
-47.05M
-40.31M
-42.30M
-44.96M
Other non operating income
-
-
-
-
EBT including unusual items
-43.48M
-39.07M
-39.68M
-42.73M
EBT excluding unusual items
-43.48M
-37.17M
-39.68M
-42.73M
Income tax expense
654.00K
92.00K
38.00K
35.00K
Effective tax rate
-1.50%
-0.24%
-0.10%
-0.08%
Other operating expenses
-
-
-
-
Net income
-44.13M
-39.16M
-39.72M
-42.76M
Net profit margin
-2,734.45%
-3,014.93%
-4,539.09%
-4,762.03%
Earnings per share
-1.06
-0.94
-0.95
-1.01
Interest and investment income
3.57M
3.14M
2.62M
2.24M
Interest expense
-
-
-
-
Net interest expenses
3.57M
3.14M
2.62M
2.24M
Depreciation and amortization charges
-
-
-
-
EBITDA
-45.82M
-39.42M
-41.50M
-44.12M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps